X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Abbott India with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs MYLAN (US) - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   MYLAN
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
MYLAN
Dec-14
ABBOTT INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs6,1104,249-   
Low Rs3,9962,995-   
Sales per share (Unadj.) Rs1,552.21,454.8-  
Earnings per share (Unadj.) Rs188.8175.2-  
Cash flow per share (Unadj.) Rs196.4282.1-  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6723.2-  
Shares outstanding (eoy) m21.25378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.32.5 130.7%   
Avg P/E ratio x26.820.7 129.5%  
P/CF ratio (eoy) x25.712.8 200.4%  
Price / Book Value ratio x6.35.0 126.6%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,370,471 7.8%   
No. of employees `0003.325.0 13.3%   
Total wages/salary Rs m3,9370-   
Avg. sales/employee Rs Th9,929.322,017.4 45.1%   
Avg. wages/employee Rs Th1,185.10-   
Avg. net profit/employee Rs Th1,207.72,652.4 45.5%   
INCOME DATA
Net Sales Rs m32,985550,436 6.0%  
Other income Rs m1,170-3,209 -36.5%   
Total revenues Rs m34,155547,228 6.2%   
Gross profit Rs m5,245136,896 3.8%  
Depreciation Rs m16240,427 0.4%   
Interest Rs m3823,743 0.2%   
Profit before tax Rs m6,21569,518 8.9%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2032,923 75.3%   
Profit after tax Rs m4,01266,309 6.1%  
Gross profit margin %15.924.9 63.9%  
Effective tax rate %35.44.2 842.8%   
Net profit margin %12.212.0 101.0%  
BALANCE SHEET DATA
Current assets Rs m22,655483,906 4.7%   
Current liabilities Rs m6,681378,318 1.8%   
Net working cap to sales %48.419.2 252.5%  
Current ratio x3.41.3 265.1%  
Inventory Days Days6578 83.0%  
Debtors Days Days29107 27.2%  
Net fixed assets Rs m835127,342 0.7%   
Share capital Rs m21319,465 1.1%   
"Free" reserves Rs m16,7150-   
Net worth Rs m16,928273,621 6.2%   
Long term debt Rs m0408,763 0.0%   
Total assets Rs m24,1621,102,120 2.2%  
Interest coverage x163.73.9 4,167.4%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.40.5 273.3%   
Return on assets %16.88.2 205.2%  
Return on equity %23.724.2 97.8%  
Return on capital %36.913.6 271.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,4380-   
CASH FLOW
From Operations Rs m1,52772,355 2.1%  
From Investments Rs m-2,148-57,061 3.8%  
From Financial Activity Rs m-1,024-19,066 5.4%  
Net Cashflow Rs m-1,646-3,772 43.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.3 Rs / USD

Compare ABBOTT INDIA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ABBOTT INDIA With: ELDER PHARMA  ALEMBIC PHARMA  VENUS REMEDIES  CIPLA  SANOFI INDIA  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 21, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS